Stars align as ex-True North team nabs an­oth­er $90M to build out biotech con­stel­la­tion

Star Ther­a­peu­tics, which cre­at­ed two an­ti­body-fo­cused biotech star­tups with more in the works, has now reeled in a $90 mil­lion Se­ries C.

The round, dis­closed Tues­day morn­ing, brings the Bay Area biotech’s to­tal fi­nanc­ing to more than $190 mil­lion since it was found­ed in 2018. (It lat­er emerged from stealth in ear­ly 2022.)

Star’s biotech star­tups Ve­ga Ther­a­peu­tics and Elec­tra Ther­a­peu­tics fo­cus on treat­ing var­i­ous hema­to­log­i­cal and im­muno-on­col­o­gy in­di­ca­tions with an­ti­bod­ies cre­at­ed in-house.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER